Transdermal Dihydrotestosterone Treatment of 'Andropause'

References

• Bardin C W., Swerdloff R S., Santen R J. Androgens: risks and benefits. J Clin Endocrinol Metab 1991; 73: 4–7
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221–4
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman H A., McKinlay J B., Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991; 73: 1016–25
   PubMed Web of Science ®Google Scholar
• Nahoul K, Roger M. Age-related decline of plasma bio-available testosterone in adult men. J Steroid Biochem 1990; 35: 293–9
   PubMedGoogle Scholar
• Purifoy F E., Koopmans L H., Mayes D M. Age differences in serum androgen levels in normal adult males. Human Biol 1981; 53: 499–511
   PubMed Web of Science ®Google Scholar
• Glass A R., Swerdloff R S., Dahms W T., Atkinson R L. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. Endocrinology 1977; 100: 212
   Google Scholar
• Khaw K T., Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675–82
   PubMedGoogle Scholar
• Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992; 35: 173–7
   PubMed Web of Science ®Google Scholar
• Dai W S., Gutai J P., Kuller L H., Laporte R E., Falvo-Gerard L, Caggiula A. Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Cardiol 1984; 53: 1259–63
   PubMed Web of Science ®Google Scholar
• Hamalalnen E, Adlercreutz H, Ehnholm C, Puska P. Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 1986; 35: 535–41
   PubMed Web of Science ®Google Scholar
• Bonithon-Kopp C, Scarabin P Y., Bara L, Castanier M, Jacqueson A, Roger M. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 1988; 71: 71–6
   PubMed Web of Science ®Google Scholar
• Breier C, Muhlberger V, Drexel H, et al. Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease. Lancet 1985; 1242–4
   PubMed Web of Science ®Google Scholar
• Finkelstein J S., Klibanski A, Near R M., Greenspan S L., Van den Crowley W F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106: 354–61
   PubMed Web of Science ®Google Scholar
• Woolf P D., Hamlll R W., McDonald J V., Lee L A., Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444–50
   PubMed Web of Science ®Google Scholar
• Burris A S., Banks S M., Carter C S., Davidson J M., Sherins R J. A long-term, prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297–304
   PubMedGoogle Scholar
• Cunningham G R., Hirshkowitz M, Korenman S G., Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 1990; 70: 792–7
   PubMed Web of Science ®Google Scholar
• Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5α-dihydrotestosterone and oestradiol-17/3 in blood of normal men. Maturitas 1980; 2: 109–18
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol 1972; 34: 730–5
   PubMed Web of Science ®Google Scholar
• Brlnd J, Strain G, Miller L, Zumoff B, Vogelman J, Orentreich N. Obese men have elevated plasma levels of estrone sulfate. Intern J Obes 1990; 14: 483–6
   PubMed Web of Science ®Google Scholar
• Klaiber E L., Broverman D M., Van den Hochman J S., Sacks G M., Dalen J E. Serum estrogen levels in men with acute myocardial infarction. Am J Med 1982; 73: 872–81
   PubMed Web of Science ®Google Scholar
• Barth J D., Jansen H, Hugenholtz P G., Birkenhager J C. Post-heparin lipases, lipids and related hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis 1983; 48: 235–41
   PubMed Web of Science ®Google Scholar
• Mendoza S G., Zerpa A, Carrasco H, et al. Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. artery 1983; 12: 1–23
   PubMedGoogle Scholar
• Klaiber E L., Broverman D M., Dalen J E. Serum estradiol levels in male cigarette smokers. Am J Med 1984; 77: 858–62
   PubMed Web of Science ®Google Scholar
• Mooradian A D., Morley J E., Korenman S G. Biological actions of androgens. Endocr Rev 1987; 8: 1–28
   PubMed Web of Science ®Google Scholar
• Lignferes B de, Morville R. Treatment of male hypogonadism by topical administration of androgens. Percutaneous absorption of steroids., P Mauvais-Jarvis, C FH Vickers, J Wepierre. Academic Press, London 1980; 273–83
   Google Scholar
• Chemama D, Morville R, Flet J, et al. Percutaneous absorption of 5α-dihydrotestosterone in man. II. Percutaneous administration of 5α-dihydrotestosterone in hypogonadal men with adiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. Int J Androl 1982; 5: 595–606
   PubMedGoogle Scholar
• Kuhn J M., Laudat M H., Van den Bricaire H, Luton J P. Traitement androgénique percutané des hypogonadismes masculins. Efficacité comparée de la testosterone et de la dihydrotestostérone: étude de 40 observations. Contracept Fert Sex 1986; 14: 1031–6
   Google Scholar
• Tenover J S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Deslypere J P. Long-term transdermal dihydrotestostérone therapy: effects on pituitary gonadal axis and plasma lipoproteins. Maturitas 1985; 7: 281–287
   PubMed Web of Science ®Google Scholar
• Basdevant A, Blache D, Van den Ponsin G, Simon P, Guy-Grand B. Hepatic lipase activity during oral and parenteral 17β-estradiol replacement therapy: high-density lipoprotein increase may not be antiatherogenic. Fertil Steril 1991; 55: 1112–7
   PubMed Web of Science ®Google Scholar
• Adams M R., Clarkson T B., Shlvely C A., Parks J S., Kaplan J R. Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol 1990; 163: 1388–93
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973; 226: 652–7
   PubMedGoogle Scholar
• Voogt H J de, Smith P H., Pavone-Macaluso M, Van den Suclu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from european organization for research on treatment of cancer trials 30761 and 30762. J Urol 1986; 135: 303–7
   PubMed Web of Science ®Google Scholar
• Agardh C D., Nilsson-Ehle P, Lundgren R, Gustafson A. The influence of treatment with estrogens and estramustine phosphate of platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma. J Urol 1984; 132: 1021–4
   PubMed Web of Science ®Google Scholar
• Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshl A. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate 1992; 21: 35–9
   PubMed Web of Science ®Google Scholar
• Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1: 329–36
   PubMedGoogle Scholar
• Forbes G B., Porta C R., Herr B E., Griggs R C. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA 1992; 267: 397–9
   PubMed Web of Science ®Google Scholar
• Cohen J C., Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64: 960–3
   PubMed Web of Science ®Google Scholar
• Geller J, Slonlt L R., Connors K, Hoffman R M. Measurement of androgen sensitivity in the human prostate in in vitro, three-dimensional histoculture. Prostate 1992; 21: 269–78
   PubMed Web of Science ®Google Scholar
• Herold M. Andractim pharmacologic report. Besins-Iscovesco Laboratories. 1976, Unpublished data
   Google Scholar
• Walker I D., Davidson J F. Long-term fibrinolytic enhancement with anabolic steroid therapy: a five-year study. Progress in chemical fibrinolysis and thrombolysis., J F. Davidson, R M. Rowan, M M. Samama, P C. Desnoyers. Raven Press, New York 1978; 3: 491–9
   Google Scholar
• Feamley G R., Chakrabarti R. Increase of blood fibrinolytic activity by testosterone. Lancet 1962; 128–32
   PubMed Web of Science ®Google Scholar
• Bennet A, Caron P, Sie P, Louvet J P., Bazex J. Ulcères de jambe post-phlébitiques et caryotype XYY: tests de fibrinolyse et fonction androgénique. Ann Dermatol Venereol 1987; 114: 1097–101
   PubMedGoogle Scholar
• Johnson M, Ramey E, Ramwell P W. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977; 232: H381–5
   PubMed Web of Science ®Google Scholar
• Rosenblum W I., El-Sabban F, Nelson G H., Allison T B. Effects in mice of testosterone and dihydrotestostérone on platelet aggregation in injured arterioles and ex vivo. Thrombosis Res 1987; 45: 719–728
   PubMed Web of Science ®Google Scholar
• Ferenchik G S. Are androgenic steroids thrombogenic?. N Engl J Med 1990; 322: 476
   Web of Science ®Google Scholar
• Wagner J D., Clarkson T B., StClair R W., Schwenke D C., Shively C A., Adams M R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal Cynomolgus monkeys. J Clin Invest 1991; 88: 1995–2002
   PubMed Web of Science ®Google Scholar
• Jaffe M D. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977; 39: 1217–22
   PubMedGoogle Scholar
• Wolinsky H. Effect of androgen treatment on the male rat aorta. J Clin Invest 1972; 51: 2552–5
   PubMed Web of Science ®Google Scholar
• Kolata G. New puzzles over estrogen and heart disease. Science 1983; 220: 1137–8
   PubMed Web of Science ®Google Scholar
• Matsumoto A M. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab 1990; 70: 282–7
   PubMed Web of Science ®Google Scholar
• Garraway M W., Collins G N., Lee R J. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71
   PubMed Web of Science ®Google Scholar
• Bartsch W, Krieg M, Becker H, Mohrmann J, Voigt K D. Endogenous androgen levels in epithelium and stroma of human benign prostatic hyperplasia and normal prostate. Acta Endocrinol 1982; 100: 634–40
   PubMedGoogle Scholar
• Walsh P C., Hutchins G M., Ewing L L. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 1983; 72: 1772–7
   PubMed Web of Science ®Google Scholar
• Bolton N J., Lukkarinen O, Vlhko R. Concentrations of androgens in human benign prostatic hypertrophic tissues incubated for up to three days. Prostate 1986; 9: 159–67
   PubMed Web of Science ®Google Scholar
• Gabrilove J L., Levine A C., Kirschenbaum A, Droller M. Effect of long-acting gonadotropin-releasing hormone analog (Leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69: 629–32
   PubMed Web of Science ®Google Scholar
• Bosch R JLH, Griffiths D J., Blom J HM, Schroeder F H. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 1989; 141: 68–72
   PubMed Web of Science ®Google Scholar
• Gormley G J., Stoner E, Bruskewitz R C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91
   PubMed Web of Science ®Google Scholar
• McConnell J D., Wilson J D., George F W., Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8
   PubMed Web of Science ®Google Scholar
• Stone N N., Fair R R., Fishman J. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 1986; 9: 311–8
   PubMed Web of Science ®Google Scholar
• Bartsch W, Klein H, Sturenburg H J., Voigt K D. Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition. J Steroid Biochem 1987; 27: 1–3
   Google Scholar
• Isaacs J T., Coffey D S. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2: 33–50
   PubMedGoogle Scholar
• Henderson D. Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors. Ann Med 1991; 23: 201–3
   PubMed Web of Science ®Google Scholar
• Walsh P C., Wilson J D. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976; 57: 1093–7
   PubMed Web of Science ®Google Scholar
• Pollard M, Snyder D L., Luckert P H. Dihydrotestosterone does not induce prostate adenocarcinoma in L-W rats. Prostate 1987; 10: 325–31
   PubMed Web of Science ®Google Scholar
• Habenicht U F., Schwartz K, Neumann F, Van den Etreby M F. Induction of estrogen-related hyperplastic changes in the prostate of the Cynomolgus Monkey by androstenedione and its antagonization by the aromatase inhibitor 1-methylandrosta-1,4-diene-3,17-dione. Prostate 1987; 11: 313–26
   PubMed Web of Science ®Google Scholar
• Tunn U W., Kaivers P, Schweikert H U. Conservative treatment of human prostatic hyperplasia. Regulation of androgen action., N Bruchovsky, A Chapdelaine, F Neumann. Bruckner R, Berlin 1985; 87–90
   Google Scholar
• Schulze H, Claus S. Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 1990; 16: 331–43
   PubMed Web of Science ®Google Scholar
• Matzkin H, Soloway M S. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992; 21: 309–14
   Google Scholar
• Shao T C., Tindall D J., Cunningham G R. Age dependency of androgen and estrogen effects on incorporation of (3H)-thymidine by rat prostates in organ culture. Prostate 1986; 8: 349–62
   PubMed Web of Science ®Google Scholar
• Tenniswood M. Role of epithelial-stromal interactions in the control of gene expression in the prostate: an hypothesis. Prostate 1986; 9: 375–85
   PubMed Web of Science ®Google Scholar
• Mori H, Maki M, Oishi K, et al. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 1990; 16: 71–80
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology. Mol Cell Endocrinol 1991; 78: 113–7
   PubMed Web of Science ®Google Scholar
• Hemsell D L., Grodin J M., Brenner P F., Sliteri P K., Macdonald P C. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38: 476–9
   PubMed Web of Science ®Google Scholar
• Levine A C., Kirschenbaum A, Droller M, Gabrilove J L. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. J Urol 1991; 146: 790–3
   PubMed Web of Science ®Google Scholar
• Rosner W, Hryb D J., Khan M S., Nakhla A M., Romas N A. Sex hormone-binding globulin: anatomy and physiology of a new regulatory system. J Steroid Biochem Molec Biol 1991; 40: 813–20
   PubMed Web of Science ®Google Scholar
• Plymate S R., Loop S M., Hoop R C., et al. Effect of sex hormone binding globulin on human prostatic carcinoma. J Steroid Biochem Molec Biol 1991; 40: 833–9
   PubMed Web of Science ®Google Scholar
• Tuohimaa P. Control of cell proliferation in male accessory sex glands. Male accessory glands., E Spring-Mills, E SE Hafez. Elsevier, Amsterdam 1980; 131–53
   Google Scholar